Background: The role of low-carbohydrate ketogenic diet (LCKD) as an adjuvant therapy in antitumor treatment is not well established. This systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted to investigate the efficacy of LCKD as an adjuvant therapy in antitumor treatment compared to non-ketogenic diet in terms of lipid profile, body weight, fasting glucose level, insulin, and adverse effects; Methods: In this study, databases such as PubMed, Web of Science, Scopus, CINAHL, and Cochrane trials were searched. Only RCTs that involved cancer participants that were assigned to dietary interventions including a LCKD group and a control group (any non-ketogenic dietary intervention) were selected. Three reviewers independently extracted the data, and the meta-analysis was performed using a fixed effects model or random effects model depending on the I2 value or p-value; Results: A total of six articles met the inclusion/exclusion criteria. In the overall analysis, the post-intervention results = standard mean difference, SMD (95% CI) showed total cholesterol (TC) level = 0.25 (−0.17, 0.67), HDL-cholesterol = −0.07 (−0.50, 0.35), LDL-cholesterol = 0.21 (−0.21, 0.63), triglyceride (TG) = 0.09 (−0.33, 0.51), body weight (BW) = −0.34 (−1.33, 0.65), fasting blood glucose (FBG) = −0.40 (−1.23, 0.42) and insulin = 0.11 (−1.33, 1.55). There were three outcomes showing significant results in those in LCKD group: the tumor marker PSA, p = 0.03, the achievement of ketosis p = 0.010, and the level of satisfaction, p = 0.005; Conclusions: There was inadequate evidence to support the beneficial effects of LCKDs on antitumor therapy. More trials comparing LCKD and non-KD with a larger sample size are necessary to give a more conclusive result.
The findings for the roles of dairy products, calcium, and vitamin D on ovarian cancer risk remain controversial. We aimed to assess these associations by using an updated meta-analysis.Five electronic databases (e.g., PubMed and Embase) were searched from inception to December 24, 2019. Pooled relative risks (RRs) with 95% confidence intervals (CIs) were calculated. A total of 29 case-control or cohort studies were included. For comparisons of the highest vs. lowest intakes, higher whole milk intake was associated with increased ovarian cancer risk (RR: 1.35, 95% CI: 1.15, 1.59), whereas decreased risks were observed for higher intakes of low-fat milk (RR: 0.84, 95% CI: 0.73, 0.96), dietary calcium (RR: 0.71, 95% CI: 0.60, 0.84), and dietary vitamin D (RR: 0.80, 95% CI: 0.67, 0.95). Additionally, for every 100-g/d increment, increased ovarian cancer risks were found for total dairy products (RR: 1.03, 95% CI: 1.01, 1.04) and for whole milk (RR: 1.07, 95% CI:1.03, 1.11); however, decreased risks were found for a 100-g/d increased intakes of low-fat milk (RR: 0.95, 95% CI: 0.91, 0.99), cheese (RR: 0.87, 95% CI: 0.76, 0.98), dietary calcium (RR: 0.96, 95% CI: 0.95, 0.98), total calcium (RR: 0.98, 95% CI: 0.97, 0.99), dietary vitamin D (RR: 0.92, 95% CI: 0.87, 0.97), and increased levels of circulating vitamin D (RR: 0.84, 95% CI: 0.72, 0.97). These results show that whole milk intake might contribute to a higher ovarian cancer risk, whereas low-fat milk, dietary calcium, and dietary vitamin D might reduce the risk.Downloaded from https://www.cambridge.org/core. IP address: 44.RR, relative risk; 95% CI, 95% confidence interval; I 2 , variation in estimated attributable to heterogeneity. * P-value of Z-test for the significance of the pool RRs and 95%CIs. † P-value of Q-test for between-study heterogeneity test. ‡ The analyses of circulating vitamin D were based on three nested case-control study.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.